A Phase 3 interventional study of aflibercept and laser photocoagulation in Retinopathy of Prematurity, sponsored by Regeneron Pharmaceuticals. Completed at 52 sites in 13 countries. Per ClinicalTrials.gov, last updated 2023-07-20.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Retinopathy of Prematurity with a site in United States — 6 open to participants now, 10 under way, none of them phase 3. Retinopathy of Prematurity · United States.
Among the 51 studies in Retinopathy of Prematurity with a site in United States, this one is the 13th largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2019, is one of 8 in phase 3, and was the 36th registered.
169 studies on the registry are indexed under Retinopathy of Prematurity; 27 are open to participants now.
Browse Retinopathy of Prematurity studies →6 of the 51 studies in Retinopathy of Prematurity with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 0 days–9 mo
FELIQS INC. · Sites in United States
Ages 4 days–5 days
Vanderbilt University Medical Center · Sites in United States
Ages 24 wk–34 wk
Duke University · Sites in United States
Ages up to 2 mo
Duke University · Sites in United States
Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 19 Retinopathy of Prematurity studies recruiting now, 7 (37%) set no upper age limit and 12 (63%) stop at 75 or younger; 19 take children under 18; 4 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 13 · Phase 3 11 · Phase 4 1
First in 1986; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 127 is above the median of 82 across 102 interventional studies indexed under Retinopathy of Prematurity.
Median enrollment 114 across the 32 interventional studies, 102 across the 15 observational. Of the 35 that completed or were terminated, 14 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 51 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 2 studies filed under Retinopathy of Prematurity — fewer than ten, so there is no comparison to draw.
3 of the studies in Retinopathy of Prematurity with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07093255FELIQS INC.Safety, PK and PD of FLQ-101 in Premature Neonates | 2026-12-31 |
| NCT04995341Duke UniversityRetinal Microanatomy in Retinopathy of Prematurity (BabySTEPS2) | 2027-03-31 |
| NCT05558059Duke UniversityImaging Retinal Vasculature in Infant Eyes | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 51 studies in Retinopathy of Prematurity with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to assess the efficacy of aflibercept compared to laser in patients diagnosed with retinopathy of prematurity (ROP). The secondary objectives of the study are to assess the need for a second treatment modality, to assess the recurrence of ROP in the study and to assess the safety and tolerability of aflibercept.
Key Inclusion Criteria:
Patients with treatment-naïve retinopathy of prematurity (ROP) classified according to the International Classification for ROP in at least one eye as:
Key Exclusion Criteria:
NOTE: Other protocol defined inclusion/exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive a single intravitreal (IVT) injection per eligible eye at baseline.
Drug: aflibercept
Patients will undergo laser treatment in each eligible eye at baseline.
Procedure: laser photocoagulation
Administered IVT
Also known as: EYLEA®, REGN3, VEGF trap-eye, BAY86-5321
Transpupillary conventional laser will be administered according to standard local procedures.
Percentage of Participants With Absence of Active Retinopathy of Prematurity (ROP) and Unfavorable Structural Outcomes From Baseline to Week 52 of Chronological Age
Active ROP was ROP requiring treatment and unfavorable structural outcome was defined as retinal detachment, macular dragging, macular fold, or retrolental opacity. For participants with both eyes enrolled in the study, both eyes must have met the endpoint. Participants with only one study eye enrolled were responders if the respective eye responded.
Time frame: Baseline to week 52 of chronological age
Percentage of Participants Requiring Intervention With a Second Treatment Modality From Baseline to Week 52 of Chronological Age
Second treatment modality includes any treatment in addition to that assigned to the participant at baseline. This includes per-protocol rescue treatment (laser for aflibercept group, aflibercept for laser group), anti-VEGF agents not part of study protocol (e.g., bevacizumab, ranibizumab, commercially-available aflibercept not provided as study medication), or any ocular surgery for the management of any retinal pathology secondary to ROP (e.g., victrectomy, scleral buckle for retinal detachments).
Time frame: Baseline to to week 52 of chronological age
Percentage of Participants With Recurrence of ROP Through Week 52 of Chronological Age
Recurrence of disease is defined as the reappearance of the disease requiring further treatment (including retreatment or rescue), where both "presence of ROP" and "presence of active ROP requiring treatment" are marked as "Yes", after initial regression. Here, the initial regression is defined as, at a particular visit, absence of ROP or ROP treatment not required for active ROP, i.e., presence of ROP is marked as "No" or the presence of active ROP requiring treatment is marked as "No."
Time frame: Baseline to week 52 of chronological age
Percentage of Participants With Ocular Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
Time frame: Baseline to Week 52 of chronological age
Percentage of Participants With Systematic (Non-ocular) TEAEs and TESAEs
Time frame: Baseline to Week 52 of chronological age
137 participants were screened, 127 were randomized.
| Milestone | Laser Photocoagulation | Aflibercept 0.4 mg |
|---|---|---|
| Started | 27 | 93 |
| Completed | 26 | 87 |
| Not completed | 1 | 6 |
| Withdrew: Withdrawal by parent/guardian | 1 | 2 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 3 |
Active ROP was ROP requiring treatment and unfavorable structural outcome was defined as retinal detachment, macular dragging, macular fold, or retrolental opacity. For participants with both eyes enrolled in the study, both eyes must have met the endpoint. Participants with only one study eye enrolled were responders if the respective eye responded.
| Percentage of participants | Laser Photocoagulation | Aflibercept 0.4 mg |
|---|---|---|
| Percentage of Participants With Absence of Active Retinopathy of Prematurity (ROP) and Unfavorable Structural Outcomes From Baseline to Week 52 of Chronological Age | 77.8 | 79.6 |
Second treatment modality includes any treatment in addition to that assigned to the participant at baseline. This includes per-protocol rescue treatment (laser for aflibercept group, aflibercept for laser group), anti-VEGF agents not part of study protocol (e.g., bevacizumab, ranibizumab, commercially-available aflibercept not provided as study medication), or any ocular surgery for the management of any retinal pathology secondary to ROP (e.g., victrectomy, scleral buckle for retinal detachments).
| Percentage of participants | Laser Photocoagulation | Aflibercept 0.4 mg |
|---|---|---|
| Percentage of Participants Requiring Intervention With a Second Treatment Modality From Baseline to Week 52 of Chronological Age | 18.5 | 15.1 |
Recurrence of disease is defined as the reappearance of the disease requiring further treatment (including retreatment or rescue), where both "presence of ROP" and "presence of active ROP requiring treatment" are marked as "Yes", after initial regression. Here, the initial regression is defined as, at a particular visit, absence of ROP or ROP treatment not required for active ROP, i.e., presence of ROP is marked as "No" or the presence of active ROP requiring treatment is marked as "No."
| Percentage of participants | Laser Photocoagulation | Aflibercept 0.4 mg |
|---|---|---|
| Percentage of Participants With Recurrence of ROP Through Week 52 of Chronological Age | 29.6 | 39.8 |
| Percentage of participants | Laser Photocoagulation | Aflibercept 0.4 mg |
|---|---|---|
| % Ocular TEAEs | 25.9 | 18.3 |
| % Ocular TESAEs | 11.1 | 6.5 |
| Percentage of participants | Laser Photocoagulation | Aflibercept 0.4 mg |
|---|---|---|
| % Systematic TEAEs | 51.9 | 47.3 |
| % Systematic TESAEs | 7.4 | 12.9 |
Collected over From signing of informed consent form (ICF) to end of study (week 52 of chronological age visit), an average of 42 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Laser Photocoagulation | 0/27 (0%) | 12/27 (44.4%) | 12/27 (44.4%) |
| Aflibercept 0.4 mg | 1/93 (1.1%) | 32/93 (34.4%) | 40/93 (43%) |
| Event | Laser Photocoagulation | Aflibercept 0.4 mg |
|---|---|---|
| ApnoeaRespiratory, thoracic and mediastinal disorders | 2/27 | 2/93 |
| Retinal detachment Study EyeEye disorders | 2/27 | 6/93 |
| BronchiolitisInfections and infestations | 1/27 | 2/93 |
| PneumoniaInfections and infestations | 1/27 | 1/93 |
| Pneumonia viralInfections and infestations | 1/27 | 1/93 |
| Apnoeic attackRespiratory, thoracic and mediastinal disorders | 1/27 | 0/93 |
| AspirationRespiratory, thoracic and mediastinal disorders | 1/27 | 0/93 |
| Chronic respiratory diseaseRespiratory, thoracic and mediastinal disorders | 1/27 | 0/93 |
| Inguinal herniaGastrointestinal disorders | 1/27 | 2/93 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/27 | 0/93 |
| Event | Laser Photocoagulation | Aflibercept 0.4 mg |
|---|---|---|
| ConstipationGastrointestinal disorders | 4/27 | 4/93 |
| PyrexiaGeneral disorders | 4/27 | 4/93 |
| Inguinal herniaGastrointestinal disorders | 3/27 | 4/93 |
| Bronchopulmonary dysplasiaRespiratory, thoracic and mediastinal disorders | 0/27 | 7/93 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 2/27 | 5/93 |
| Bacterial disease carrierInfections and infestations | 2/27 | 1/93 |
| OsteopeniaMusculoskeletal and connective tissue disorders | 2/27 | 2/93 |
| ApnoeaRespiratory, thoracic and mediastinal disorders | 2/27 | 1/93 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/27 | 3/93 |
| WheezingRespiratory, thoracic and mediastinal disorders | 2/27 | 1/93 |
Full analysis set (FAS): All randomized participants who received any study treatment. Eyes analyzed includes all treated eyes.
| Age, Continuous(Weeks) | Laser Photocoagulation | Aflibercept 0.4 mg | Total |
|---|---|---|---|
| Mean | 11.09 ± 4.338 | 9.76 ± 3.149 | 10.06 ± 3.476 |
| Sex: Female, Male(Participants) | Laser Photocoagulation | Aflibercept 0.4 mg | Total |
|---|---|---|---|
| Female | 10 | 52 | 62 |
| Male | 17 | 41 | 58 |
| Ethnicity (NIH/OMB)(Participants) | Laser Photocoagulation | Aflibercept 0.4 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 16 | 20 |
| Not Hispanic or Latino | 22 | 72 | 94 |
| Unknown or Not Reported | 1 | 5 | 6 |
| Race/Ethnicity, Customized(Participants) | Laser Photocoagulation | Aflibercept 0.4 mg | Total |
|---|---|---|---|
| White | 11 | 26 | 37 |
| Black or African American | 2 | 6 | 8 |
| Asian | 13 | 44 | 57 |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Other | 1 | 12 | 13 |
| Not Reported | 0 | 5 | 5 |
| Retinopathy of prematurity (ROP) Zone, by eye(Eyes) | Laser Photocoagulation | Aflibercept 0.4 mg | Total |
|---|---|---|---|
| Zone I | 13 | 47 | 60 |
| Zone II | 37 | 132 | 169 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.
Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).
Data sharing details ↗ · vivli.org
Ran from Oct 2019 to primary completion in Aug 2022, 33 months.
Results were first posted in Jul 2023, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept